{"brief_title": "Safety and Pharmacokinetics of Single Intravenous Doses of Peginesatide in Healthy Volunteers", "brief_summary": "The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and minimum pharmacologically active dose of peginesatide in Healthy Volunteers.", "detailed_description": "This was a Phase 1, double-blind, placebo-controlled trial of peginesatide, an erythropoiesis stimulating agent, with approximately 7 treatment cohorts and 7 healthy volunteer participants per cohort. In each cohort of 7 participants, a ratio of 5:2 participants was randomly assigned to receive a single dose of peginesatide or placebo, respectively, administered as an intravenous infusion. Planned peginesatide dose levels were to escalate by cohort. The study was conducted at a single clinical center.", "condition": "Cancer", "intervention_type": "Drug", "intervention_name": "peginesatide", "arm_group_label": "Peginesatide 0.10 mg/kg", "other_name": "AF37702 Injection", "criteria": "Main eligibility criteria: - Participant is a healthy male, age \u2265 18 years and \u2264 40 years, with body mass index (BMI) \u2265 18 and \u2264 30 kilograms per squared meter (kg/m^2), and weight \u2265 50 and \u2264 95 kilograms (kg) - Participant has hemoglobin of \u2264 16 grams per deciliter (g/dL) at the time of study entry - Participant has normal iron stores", "gender": "Male", "minimum_age": "18 Years", "maximum_age": "40 Years", "healthy_volunteers": "Accepts Healthy Volunteers", "id": "NCT00097747.xml"}